Blockade of the renin-angiotensin system in African Americans with hypertension and cardiovascular disease
- PMID: 12556668
- PMCID: PMC8101843
- DOI: 10.1111/j.1524-6175.2003.02181.x
Blockade of the renin-angiotensin system in African Americans with hypertension and cardiovascular disease
Abstract
There is overwhelming evidence that the renin-angiotensin system plays a significant role in the pathophysiology of hypertension and target organ damage. Agents that regulate the renin-angiotensin system, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, and aldosterone antagonists, are not only effective antihypertensive agents but can prevent target organ damage. Although diuretics remain the agents of first choice for the treatment of hypertension in African Americans, ACE inhibitors have a clear role in the management of these patients. ACE inhibitors (usually when used with a diuretic) have been shown to reduce morbidity and mortality in a wide range of patient groups. ACE inhibitors are infrequently used in African Americans because of a belief that these agents are ineffective in this racial group; however, when adequate dosing and appropriate combinations are used, ACE inhibitor therapy provides effective blood pressure control. In particular, the addition of diuretics to ACE inhibitor therapy ameliorates the racial differences in efficacy seen when ACE inhibitors are administered as monotherapy. Although further confirmation in additional clinical trials is required, increased use of these agents in African Americans will likely result in a reduction in target organ damage.
Copyright 2003 Le Jacq Communications, Inc.
Similar articles
-
Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?Drugs. 2010 Jul 9;70(10):1215-30. doi: 10.2165/11537910-000000000-00000. Drugs. 2010. PMID: 20568830 Review.
-
Rationale for angiotensin II receptor blockers in patients with low-renin hypertension.Am J Kidney Dis. 2000 Sep;36(3 Suppl 1):S24-30. doi: 10.1053/ajkd.2000.9688. Am J Kidney Dis. 2000. PMID: 10986156 Review.
-
Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?Clin Ther. 2007 Sep;29(9):1803-24. doi: 10.1016/j.clinthera.2007.09.019. Clin Ther. 2007. PMID: 18035185 Review.
-
Renin-angiotensin-aldosterone system inhibition: overview of the therapeutic use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, and direct renin inhibitors.Prim Care. 2014 Dec;41(4):765-78. doi: 10.1016/j.pop.2014.08.002. Epub 2014 Sep 29. Prim Care. 2014. PMID: 25439533 Review.
-
Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.J Hypertens Suppl. 1997 Dec;15(6):S31-6. doi: 10.1097/00004872-199715066-00007. J Hypertens Suppl. 1997. PMID: 9493125 Review.
Cited by
-
Blood pressure effects of high-dose amlodipine-benazepril combination in Black and White hypertensive patients not controlled on monotherapy.Drugs R D. 2012 Jun 1;12(2):57-64. doi: 10.2165/11633430-000000000-00000. Drugs R D. 2012. PMID: 22571394 Free PMC article. Clinical Trial.
-
Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension.Am J Hypertens. 2019 Jun 11;32(7):668-675. doi: 10.1093/ajh/hpz022. Am J Hypertens. 2019. PMID: 30753254 Free PMC article.
-
Elevated peripheral blood mononuclear cell-derived superoxide production in healthy young black men.Am J Physiol Heart Circ Physiol. 2015 Mar 1;308(5):H548-52. doi: 10.1152/ajpheart.00784.2014. Epub 2014 Dec 19. Am J Physiol Heart Circ Physiol. 2015. PMID: 25527783 Free PMC article.
-
Beta blocker therapy after acute myocardial infarction in patients with heart failure and systolic dysfunction.Heart Fail Rev. 2004 Apr;9(2):107-13. doi: 10.1023/B:HREV.0000046365.53467.f4. Heart Fail Rev. 2004. PMID: 15516858 Review.
-
Rationale and Design of the Mechanistic Potential of Antihypertensives in Preclinical Alzheimer's (HEART) Trial.J Alzheimers Dis. 2018;61(2):815-824. doi: 10.3233/JAD-161198. J Alzheimers Dis. 2018. PMID: 29254080 Free PMC article.
References
-
- Saunders E. Tailoring treatment to minority patients. Am J Med. 1990;88(Suppl 3B):21S–23S. - PubMed
-
- American Heart Association . 2002 Heart and Stroke Statistical Update. Dallas , TX : American Heart Association, 2001.
-
- Jamerson K, De Quattro V. The impact of ethnicity on response in antihypertensive therapy. Am J Med. 1996;101 (suppl 3A):22S–32S. - PubMed
-
- Alexander M, Grumbach K, Remy L, et al. Congestive heart failure hospitalizations and survival in California: patterns according to race/ethnicity. Am Heart J. 1999;137:919–927. - PubMed
-
- Dries DL, Exner DV, Gersh BJ, et al. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med. 1999;340:609–616. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous